DaraxonrasibelironrasibpembrolizumabNSCLCanti-PD-1 immunotherapyimmunotherapy
… cancer (NSCLC) where immunotherapy is standard of care.Methods Daraxonrasib, a RAS(ON) multi-selective inhibitor, and elironrasib, a RAS(ON…
1articles mentioning drugs
4drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: elironrasib ×
elironrasib
This drug is selected. Its supporting articles are shown below.